Abstract

Fremanezumab (Ajovy) is a new anti‐CGRP monoclonal antibody therapy indicated for the prophylaxis of migraine in adults. This article outlines its properties, efficacy, adverse effects and place in therapy.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call